Denali Therapeutics Inc.
Biotechnology company · South San Francisco, California, United States · Nasdaq: DNLI
Denali Therapeutics Inc. is a biotechnology company headquartered in South San Francisco, California, United States. Its shares trade on Nasdaq under the ticker DNLI. It has reported private securities offerings to the US SEC, most recently $500 million sold in a notice filed in 2024.
Denali Therapeutics at a glance
What does Denali Therapeutics do?
Private fundraising reported to the SEC
1 Form D notice; the most recent reported $499.7 million sold (2024).
Frequently asked questions about Denali Therapeutics
Where is Denali Therapeutics headquartered?
Denali Therapeutics Inc. is headquartered in South San Francisco, California, United States.
What does Denali Therapeutics do?
Denali Therapeutics Inc. is a biotechnology company. Its SEC industry classification is Biological Products, (No Diagnostic Substances).
Is Denali Therapeutics a public company?
Yes. Denali Therapeutics Inc. trades on Nasdaq under the ticker DNLI.
Similar companies
- Alector, Inc.South San Francisco, California, United States
- Vaxart, Inc.South San Francisco, California, United States
- Aligos Therapeutics, Inc.South San Francisco, California, United States
- PROFUSA, Inc.South San Francisco, California, United States
- Quince Therapeutics, Inc.South San Francisco, California, United States
- Allogene Therapeutics, Inc.South San Francisco, California, United States
- Sutro Biopharma, Inc.South San Francisco, California, United States
- Electra Therapeutics, Inc.South San Francisco, California, United States
Need a CRO or CDMO for your next study?
Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.
Compare quotesSources
Location data: GeoNames (geonames.org), CC BY 4.0.
Last updated 2026-09-23.